Jed Latkin, CEO, COO & CFO at NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB), bought 5,400 shares at $1.91 ($10K) on 2019-05-13, disclosed to the SEC on 2019-05-15.
Open-market purchase of $10k NAVB by CEO, COO & CFO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.91 | 2,400 | $5K | 47.2% |
| 2 | $1.84 | 2,000 | $4K | 37.9% |
| 3 | $1.45 | 1,000 | $1K | 14.9% |
| Total | $1.80 avg | 5,400 | $10K | 100% |
| Filing → |
| NAVB | BUY | 2019-05-17 | $4K | — | Filing → |
| NAVB | BUY | 2017-05-31 | $3K | — | Filing → |
| NAVB | BUY | 2017-05-23 | $11K | — | Filing → |